(eukaryotic translation initiation factor) eIF4 Inhibitors

Salubrinal inhibits eIF2α dephosphorylation, leading to prolonged phosphorylation, which reduces translation initiation.

GSK2606414 inhibits the activity of PERK, a kinase that phosphorylates eIF2α, reducing eIF2α phosphorylation levels.

Cisplatin indirectly affects eIF2α by causing DNA damage, triggering the integrated stress response and eIF2α phosphorylation.

Thapsigargin induces ER stress, activating PERK and leading to eIF2α phosphorylation, thereby inhibiting protein synthesis.

Etoposide causes DNA damage, which could lead to a cellular stress response, potentially diverting cellular resources from RNAi pathways and thus down-regulating eIF2C2.

By acting as a pyrimidine analog, 5-Fluorouracil might disrupt nucleotide metabolism. This disruption could indirectly affect RNAi components by hampering RNA synthesis, leading to decreased eIF2C2 levels.

Bortezomib inhibits the proteasome, affecting protein turnover. This can disrupt the balance of cellular proteins, potentially decreasing the stability or synthesis of eIF2C2.

Actinomycin D hinders RNA synthesis by intercalating DNA. This can lead to a general down-regulation of RNA-derived processes, which might include a decrease in eIF2C2 levels.

By inhibiting protein synthesis, Cycloheximide might halt the production of new eIF2C2 molecules, leading to a net decrease in eIF2C2 as existing proteins degrade.

DNA damage from Doxorubicin may cause the cell to prioritize DNA repair over regular functions, potentially suppressing RNAi machinery and decreasing eIF2C2 levels.